Exact Sciences on Track for Profitability as Cologuard Continues to Drive Growth

Exact Sciences (NASDAQ: EXAS), a leader in molecular diagnostics and early cancer detection, is poised to reach profitability in the coming years. According to Visible Alpha consensus estimates, the company’s net loss is expected to narrow significantly from an estimated $203 million in 2024 to $56 million by 2025. Analysts forecast the company to become net income positive by 2026, with a projected net income of $84 million.

This positive outlook follows the U.S. FDA’s recent approval of Cologuard Plus, an enhanced version of Exact’s flagship colorectal cancer (CRC) screening test, first approved in 2014. Cologuard continues to be a major growth driver for Exact Sciences, thanks to its affordability and accuracy.

For 2024, Exact Sciences is set to generate $2.7 billion in revenue, reflecting a +10% year-over-year increase. The bulk of this growth is expected to come from the company’s screening segment, which is expected to contribute $2.1 billion—of which Cologuard will account for a dominant 98%. Despite rising competition from Guardant Health’s (NASDAQ: GH) Shield, a blood-based CRC screening test, Cologuard retains a strong market lead. Shield, though less invasive, is projected to generate $2.9 million in revenue in 2024, a small fraction of Cologuard’s expected $2 billion.